Journal ArticleDOI
Difference in Viability of CD34+ Cells in Cryopreserved Cord Blood According to Evaluation Methods
Mi Sun Ahn,Young-Woo Eom,Joon Seong Park,Jin-Hyuk Choi,Seok Yun Kang,Hyun Woo Lee,Mal Sook Yang,Hyo Eun Kim,In Keun Jang,Jong Eun Lee,Young-Jin Kim,Hugh C. Kim,Seong Hyun Jeong +12 more
Reads0
Chats0
TLDR
After thawing the cryopreserved UCB, 89% of the total MNCs and 84% of CD34+ cells were viable as identified by trypan blue exclusion assay, and the cell death rate was found to be 47% by Annexin-V/PI staining and less than 5% by DNA contents analysis.Abstract:
Background: On performing umbilical cord blood (UCB) transplantation, faster engraftment may lead better clinical outcome. Because transplanted viable cell count in UCB is related to the engraftment, accu- rate evaluation of viability of CD34+ cells in cryopreserved UCB has clinical implication. We examined the difference in viability of cells in cryopreserved UCB according to the duration of cryopreservation and different methods. Methods: A total of 60 UCB samples which were cryopreserved for 1 to 4 years were used in this study. Viability of cryopreserved cells were examined with trypan blue exclusion assay, DNA contents analysis, caspase-3 activation test, intracellular esterase activity and Annexin-V/PI staining. Results: After thawing the cryopreserved UCB, 89% of the total MNCs and 84% of CD34+ cells were viable as identified by trypan blue exclusion assay. In the CD34+ cell population, the cell death rate was found to be 47% by Annexin-V/PI staining and less than 5% by DNA contents analysis. However, cspase-3 activity failed to document apoptosis. The intracellular esterase activity test also showed a cell death rate of about 10 ∼20% at 2, 4, and 6 hours after thawing.read more
References
More filters
Book ChapterDOI
Cell death : the significance of apoptosis
TL;DR: It has proved feasible to categorize most if not all dying cells into one or the other of two discrete and distinctive patterns of morphological change, which have, generally, been found to occur under disparate but individually characteristic circumstances.
Journal ArticleDOI
Hematopoietic reconstitution in a patient with fanconi's anemia by means of umbilical-cord blood from an hla-identical sibling
Eliane Gluckman,Hal E. Broxmeyer,Arleen D. Auerbach,Henry S. Friedman,Gordon W. Douglas,Agnès Devergie,Helene Esperou,Dominique Thierry,Gérard Socié,Pierre Lehn,Scott Cooper,Denis English,Joanne Kurtzberg,Judith Bard,Edward A. Boyse +14 more
TL;DR: It is necessary to select patients suitable for vaginal or laparoscopic mesh placement for Fanconi's anemia preoperatively on the basis of prior history and once they provide informed consent for surgery.
Journal ArticleDOI
Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated Donors
Pablo Rubinstein,Carmelita Carrier,Andromachi Scaradavou,Joanne Kurtzberg,John W. Adamson,Anna Rita Migliaccio,Richard L. Berkowitz,Michael F. Cabbad,Dobrila Nl,Patricia E. Taylor,Richard E. Rosenfield,Cladd E. Stevens +11 more
TL;DR: Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution and is associated with the severity of GVHD, type of leukemia, and stage of the disease.
Journal ArticleDOI
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells
Hal E. Broxmeyer,Gordon W. Douglas,Giao Hangoc,Scott Cooper,Judith Bard,Denis English,Margaret Arny,Lewis Thomas,Edward A. Boyse +8 more
TL;DR: It was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition of anticoagulant for at least 3 days at 4 degrees C or 25 degrees C (room temperature), though not at 37 degrees C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy.
Journal ArticleDOI
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
John E. Wagner,Juliet N. Barker,Todd E. DeFor,K. Scott Baker,Bruce R. Blazar,Cindy R. Eide,Anne I. Goldman,John H. Kersey,William Krivit,Margaret L. MacMillan,Paul J. Orchard,Charles Peters,Daniel J. Weisdorf,Norma K.C. Ramsay,Stella M. Davies +14 more
TL;DR: There is a high probability of survival in recipients of UCB grafts that are disparate in no more than 2 human leukocyte antigens when the grafts contain at least 1.7 x 10(5) CD34(+) cells per kilogram of recipient's body weight, and graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less.